EA201790716A1 - Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr - Google Patents
Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfrInfo
- Publication number
- EA201790716A1 EA201790716A1 EA201790716A EA201790716A EA201790716A1 EA 201790716 A1 EA201790716 A1 EA 201790716A1 EA 201790716 A EA201790716 A EA 201790716A EA 201790716 A EA201790716 A EA 201790716A EA 201790716 A1 EA201790716 A1 EA 201790716A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fgfr
- panels
- detect
- mutant genes
- inhibitor treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
В настоящем документе раскрываются способы выявления онкологического пациента, который будет поддаваться лечению ингибитором рецептора фактора роста фибробластов (FGFR), и способы лечения страдающих раком пациентов. Такие способы включают анализ биологического образца, взятого у пациента, на наличие одного или более мутантов FGFR из панели мутантных генов FGFR. В настоящем документе также раскрываются наборы и праймеры для выявления в биологическом образце наличия одного или более генов мутантов FGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462056159P | 2014-09-26 | 2014-09-26 | |
PCT/US2015/050996 WO2016048833A2 (en) | 2014-09-26 | 2015-09-18 | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201790716A1 true EA201790716A1 (ru) | 2017-10-31 |
EA037920B1 EA037920B1 (ru) | 2021-06-07 |
Family
ID=54337343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790716A EA037920B1 (ru) | 2014-09-26 | 2015-09-18 | Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr |
Country Status (38)
Country | Link |
---|---|
US (3) | US20160090633A1 (ru) |
EP (2) | EP3198033B1 (ru) |
JP (4) | JP6766037B2 (ru) |
KR (2) | KR20220162823A (ru) |
CN (2) | CN113957146A (ru) |
AR (1) | AR102345A1 (ru) |
AU (3) | AU2015321626B2 (ru) |
CA (1) | CA2962075A1 (ru) |
CO (1) | CO2017003528A2 (ru) |
CR (1) | CR20170104A (ru) |
CY (1) | CY1125190T1 (ru) |
DK (1) | DK3198033T3 (ru) |
EA (1) | EA037920B1 (ru) |
EC (1) | ECSP17025787A (ru) |
ES (1) | ES2912567T3 (ru) |
GT (1) | GT201700059A (ru) |
HR (1) | HRP20220496T1 (ru) |
HU (1) | HUE058219T2 (ru) |
IL (2) | IL251264B (ru) |
JO (1) | JO3681B1 (ru) |
LT (1) | LT3198033T (ru) |
MA (1) | MA40761B1 (ru) |
MX (2) | MX392774B (ru) |
MY (1) | MY194567A (ru) |
NI (1) | NI201700035A (ru) |
PH (1) | PH12017500556A1 (ru) |
PL (1) | PL3198033T3 (ru) |
PT (1) | PT3198033T (ru) |
RS (1) | RS63178B1 (ru) |
SG (1) | SG11201702381QA (ru) |
SI (1) | SI3198033T1 (ru) |
SM (1) | SMT202200177T1 (ru) |
SV (1) | SV2017005415A (ru) |
TW (1) | TWI706136B (ru) |
UA (1) | UA122564C2 (ru) |
UY (1) | UY36325A (ru) |
WO (1) | WO2016048833A2 (ru) |
ZA (1) | ZA201702899B (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA031631B1 (ru) | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
WO2015111716A1 (ja) | 2014-01-24 | 2015-07-30 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
HRP20220496T1 (hr) | 2014-09-26 | 2022-05-27 | Janssen Pharmaceutica Nv | Uporaba fgfr mutantnih genskih panela kod identifikacije pacijenata s rakom koji će reagirati na liječenje s inhibitorom fgfr |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US11975002B2 (en) * | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
AU2019310594A1 (en) | 2018-07-27 | 2021-02-11 | Zepto Life Technology, Inc. | System and method for sample preparation in GMR-based detection of biomarkers |
KR20210064274A (ko) * | 2018-09-21 | 2021-06-02 | 얀센 파마슈티카 엔.브이. | 담관암종의 치료 |
CN113423402A (zh) * | 2019-02-12 | 2021-09-21 | 詹森药业有限公司 | 癌症治疗 |
CA3130460A1 (en) | 2019-03-29 | 2020-10-08 | Anne Elizabeth O'HAGAN | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
CA3130773A1 (en) | 2019-03-29 | 2020-10-08 | Peter Marie Z. De Porre | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
SG11202112932QA (en) * | 2019-05-31 | 2021-12-30 | Qed Therapeutics Inc | Methods of treating urinary system cancers |
CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
US20220307078A1 (en) * | 2019-09-09 | 2022-09-29 | Zepto Life Technology, LLC | Systems and methods for detecting genetic variation in nucleic acids |
JOP20220073A1 (ar) | 2019-09-26 | 2023-01-30 | Janssen Pharmaceutica Nv | استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية |
AU2021220285A1 (en) | 2020-02-12 | 2022-10-06 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 |
BR112022020846A2 (pt) * | 2020-04-15 | 2022-12-27 | Alkermes Pharma Ireland Ltd | Agentes imunoestimuladores em combinação com inibidores de angiogênese |
CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
EP4210702A1 (en) | 2020-09-14 | 2023-07-19 | JANSSEN Pharmaceutica NV | Fgfr inhibitor combination therapies |
CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
MX2023013802A (es) | 2021-05-19 | 2023-12-06 | Janssen Pharmaceutica Nv | Inhibidores de tirosina quinasa de fgfr para el tratamiento de tumores solidos avanzados. |
MX2024004488A (es) | 2021-10-12 | 2024-07-10 | Taris Biomedical Llc | Formulaciones y sistemas de erdafitinib para administración intravesical. |
EP4479055A1 (en) | 2022-02-18 | 2024-12-25 | TARIS Biomedical LLC | Erdafitinib formulations and osmotic systems for intravesical administration |
WO2024173377A1 (en) | 2023-02-13 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib for intravesical administration for use in the treatment of bladder cancer |
WO2024170495A1 (en) | 2023-02-13 | 2024-08-22 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
WO2024173716A1 (en) | 2023-02-17 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib for intravesical administration for use in the treatment of bladder cancer |
WO2025059602A1 (en) | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Methods of treating bladder cancer using intravesical administration of erdafitinib |
CN119219611B (zh) * | 2024-12-03 | 2025-04-18 | 南京诺源医疗器械有限公司 | 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
AU5214500A (en) | 1999-05-05 | 2000-11-21 | Centre National De La Recherche Scientifique (C.N.R.S.) | Means for detecting and treating pathologies linked to fgfr3 |
AU2003300504B2 (en) | 2002-10-01 | 2009-10-01 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
WO2004085676A1 (en) * | 2003-03-26 | 2004-10-07 | Progenika Biopharma, S.A. | In vitro method to detect bladder transitional cell carcinoma |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
EP1659175A1 (en) * | 2004-11-18 | 2006-05-24 | Institut Curie | Alterations in seborrheic keratoses and their applications |
WO2006127926A2 (en) | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
BRPI0619548A2 (pt) | 2005-12-08 | 2011-10-04 | Novartis Ag | efeitos inibidores de fgfr3 em transcrição de gene |
EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
US20100075337A1 (en) | 2007-02-27 | 2010-03-25 | Diana Graus Porta | Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof |
WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
WO2008157801A2 (en) | 2007-06-21 | 2008-12-24 | Gen-Probe Incorporated | Instrument and receptacles for performing processes |
US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
WO2013173480A1 (en) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Detection of bladder cancer recurrence |
WO2013173485A1 (en) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Detection of bladder cancers |
GB0718542D0 (en) | 2007-09-22 | 2007-10-31 | Univ Dundee | Targeted modulation of gene expression |
AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
AU2010229705A1 (en) | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
WO2011027219A1 (en) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | High throughput detection of small genomic deletions and insertions |
US9140689B2 (en) * | 2010-03-14 | 2015-09-22 | Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释-缓释渗透泵制剂 |
SG2014010276A (en) | 2011-08-18 | 2014-03-28 | Nestec Sa | Compositions and methods for detecting allelic variants |
US20130096021A1 (en) | 2011-09-27 | 2013-04-18 | Arul M. Chinnaiyan | Recurrent gene fusions in breast cancer |
AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
WO2013088191A1 (en) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
ES2746288T3 (es) * | 2012-02-28 | 2020-03-05 | Astellas Pharma Inc | Compuesto heterocíclico aromático que contiene nitrógeno |
EP2824181B1 (en) | 2012-03-08 | 2018-11-14 | Astellas Pharma Inc. | Novel fgfr3 fusion product |
US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
WO2014007369A1 (ja) * | 2012-07-05 | 2014-01-09 | 独立行政法人国立がん研究センター | Fgfr2融合遺伝子 |
EP4276200A3 (en) * | 2012-07-24 | 2024-02-14 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
RU2015102194A (ru) * | 2012-07-27 | 2016-09-20 | Дженентек, Инк. | Способы лечения связанных с fgfr3 состояний |
EA031631B1 (ru) * | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
AU2013337264B2 (en) * | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
WO2014113729A2 (en) * | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
US9777333B2 (en) | 2013-04-05 | 2017-10-03 | Life Technologies Corporation | Gene fusion |
EP3004380A2 (en) | 2013-05-27 | 2016-04-13 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Novel translocations in lung cancer |
WO2015006723A1 (en) | 2013-07-12 | 2015-01-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
US20200208224A1 (en) | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
HRP20220496T1 (hr) | 2014-09-26 | 2022-05-27 | Janssen Pharmaceutica Nv | Uporaba fgfr mutantnih genskih panela kod identifikacije pacijenata s rakom koji će reagirati na liječenje s inhibitorom fgfr |
JOP20190190A1 (ar) | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
-
2015
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 CN CN202111247854.6A patent/CN113957146A/zh active Pending
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/en active Active
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/en active Pending
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 KR KR1020227040649A patent/KR20220162823A/ko active Pending
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 CA CA2962075A patent/CA2962075A1/en active Pending
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active Active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/en active Application Filing
- 2015-09-18 MX MX2017003954A patent/MX392774B/es unknown
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
-
2022
- 2022-03-23 IL IL291633A patent/IL291633A/en unknown
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
-
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201448A patent/AU2025201448A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790716A1 (ru) | Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr | |
PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
MX2022014633A (es) | Metodos para detectar norovirus. | |
MX394474B (es) | Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo. | |
MY195999A (en) | Molecular Detection/Diagnosis Reagent for Tumor | |
EA201890512A1 (ru) | Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы | |
MX2021007667A (es) | Composiciones y metodos para detectar un contaminante biologico. | |
JOP20190199B1 (ar) | استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5 | |
EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
EP3686290A3 (en) | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer | |
WO2015120094A3 (en) | Method of identifying tyrosine kinase receptor rearrangements in patients | |
MX388084B (es) | Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa. | |
GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
EP4407047A3 (en) | Molecular detection of enterovirus and parechovirus | |
BR112015019425A2 (pt) | Métodos e kits para identificar e ajustar desvio no sequenciamento de amostras de polinucleotídeos | |
JOP20210266A1 (ar) | مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية | |
HK1250958A1 (zh) | 用於治療癌症的組合物和方法 | |
EA201992849A1 (ru) | Ингибиторы fgfr2 для лечения холангиокарциномы | |
WO2014110230A3 (en) | Methods for diagnosing cancer based on small nucleolar rna hbii-52 | |
PL413907A1 (pl) | Sposób wykrywania genetycznie uwarunkowanej zwiększonej predyspozycji do raka jelita grubego | |
PL408727A1 (pl) | Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena | |
UA92246U (ru) | Спектрофотометрический способ количественного определения зопиклона | |
UA96023U (ru) | Способ прогнозирования сращивания перелома | |
UA96056U (ru) | Способ прогнозирования сращивания перелома | |
UA94327U (ru) | Способ прогнозирования несращения перелома |